ARTICLE
10 March 2016

When has a company engaged in misleading or deceptive conduct?

WT
Watkins Tapsell

Contributor

Watkins Tapsell is a client-focused law firm with over 50 years of experience. They provide comprehensive legal support to families, individuals, small businesses, and larger companies. With six Partners and a dedicated team, they prioritize exceeding client expectations by anticipating legal changes and adapting their services to meet evolving needs. Building long-term relationships is a core value for Watkins Tapsell.
The ACCC investigates alleged breaches of the ACL and can then commence legal proceedings against an offending company.
Australia Consumer Protection

ACL AND THE CASE AGAINST NUROFEN – MISLEADING OR DECEPTIVE CONDUCT.

The Australian Consumer Law ("ACL") protects consumers from being a victim of misleading or deceptive conduct in trade or commerce. No company is immune from legal action if they are suspected of being in breach of the ACL.

ACCC case against Nurofen

The Australian Competition and Consumer Commission ("ACCC") investigates alleged breaches and has the authority to commence legal proceedings against an offending company. This was most recently the case in proceedings brought against Reckitt Benckiser (Australia) Pty Ltd ("RB"), the company behind Nurofen.

RB had released four Nurofen products, each targeted at relieving a specific type of pain, ie back pain, migraines, tension headache and period pain. The pain targeted by each product was indicated not just on the packaging, but also on its website.

Federal Court Decision

In a Federal Court decision handed down on 11 December 2015, it was held that RB:

  1. Engaged in conduct that is misleading or deceptive or likely to mislead or deceive and
  2. Engaged in conduct that is liable to mislead the public about the nature, characteristics and suitability of its products

by representing that each product was formulated to treat that type of pain and the product would specifically/ solely treat that type of pain, even though:

  1. Each of the four products had the same active ingredient and was of the same formulation;
  2. The indications approved by the Australian Register of Therapeutic Goods were the same for each product; and
  3. No product was more or less effective than the others in treating pain.

Orders made against Nurofen

RB was ordered to:

  1. For a period of 3 years, refrain from selling, marketing or promoting the four products in the current packaging or in packaging that suggests the products were formulated to treat that type of pain or specifically/solely treat that type of pain;
  2. Within 4 weeks, stop further shipment and distribution of the products;
  3. Within 3 months, remove the products from display in retail outlets;
  4. Publish a corrective notice on its website and in The Australian newspaper;
  5. Update and maintain its Consumer Protection Law Compliance Program for 3 years;
  6. Pay the ACCC costs.

RB is also likely to receive a significant pecuniary penalty, which is yet to be determined. A penalty of up to $1.1 million is available to the Court for each offence.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More